On the surface, the recent initial public offering (IPO) of the freshly minted American Healthcare REIT (AHR) has undeniably caught the eye of the investment community. The company has ambitiously sought a whopping $840 million from this public sale of its stocks, with the intent to leverage this capital for debt repayment and expansion of its portfolio – spanning senior housing, care facilities, hospitals, and a broad scope of healthcare real estates. But, like an iceberg, what lies beneath may well be more consequential than meets the eye!
A Troubling Legacy Buried in Past Performances
The roots of AHR are firmly entrenched in the amalgamation of two previously related entities – Griffin-American Healthcare REIT III (GAH III) and Grilla-American Healthcare REIT IV (GAH IV), along with their acquisition of American Healthcare Investors (AHI). Scrutinizing the ashes from which AHR has risen surfaces pressing questions concerning the IPO’s longevity. It’s a story of consistent underperformance.
Looking back, GAH III, baptized in 2012, managed a meager annualized total return of 3.9%, grossly underperforming the industry benchmark – NAREIT Healthcare REIT Index has delivered a return of 8.4% within the same timeline. The sibling, GAH IV, doesn’t paint a decidedly brighter picture either. Launched in 2015, it’s monetary performance nose-dived into the negative territory with an annual calculated return of -0.4%. Chilling figures that force us to question the merits and efficacy of their assets and management team in relation to producing sustainable returns.
The Acquisition of AHI – A Risky Bet Costly Enough?
The 2023 acquisition of AHI by AHR, though a bold move, was met with raised eyebrows and shared skepticism around the investment community. AHI’s portfolio was predominantly saturated with what classified as lower-quality skilled nursing facilities (SNFs), an asset class wresting with declining occupancy rates and cuts in government reimbursement. The steep price paid for this acquisition seems to cast a long, ominous shadow posing two profound questions – Did AHR overpay for AHI? And if so, has it loaded the new entity with more debt than it can shoulder, thereby risking its future profitability?
Three Layers of Risk that Compromise the AHR’s IPO
Flicking through AHR’s IPO prospectus, amidst the glossy assurances of diversified assets and an experienced management team, emerges salient risks that must not be ignored. If you are eying this IPO through your broker’s lens, it’s prudent to consider:
- Shortcomings with Portfolio quality: The underwhelming track record of GAH III and GAH IV suggests that the assets under AHR’s stewardship could be subpar, compromising future returns.
- Exposure to declining SNFs: AHI’s significant reliance on SNFs could potentially slow growth and profitability due to systemically challenging conditions.
- Debt from Acquisition: Overpaying for AHI’s acquisition could leave AHR susceptible to a massive debt burden, undermining its financial agility and the capacity to distribute future dividends.
The American Healthcare REIT IPO has positioned itself as an alluring opportunity for investors eyeing the healthcare real estate sector. However, the undercurrents boiling under the merger and acquisition raise red flags about AHR’s long-term prospects. It’s necessary for brokers to thoroughly assess these risk factors prior to endorsing the IPO to their clients. A meticulous evaluation of AHR’s assets, the impact of SNF exposure, and management’s plan to tackle indebtedness can prevent potential FINRA violations.
Crafted meticulously, the AHR IPO proposition is indeed a tempting fruit. But forbidden fruit often tells a cautionary tale. The alluring exterior may camouflage the perilous seeds within. Digging deeper into its bedrock is a critical step in the investing process, and due diligence shouldn’t be skimped for immediate gains. Here’s to making wise decisions.